(182) Outpatient management of bispecific related toxicities: an observational study of safety outcomes and resource utilization

Poster Abstract:

Background: Cytokine release syndrome (CRS) of any grade occurs in 42-77% of bispecific T-cell engaging therapies used in multiple myeloma or lymphoma. In response, risk mitigation strategies are required, including pre-medications, step up dosing, and close monitoring following delivery of step-up dosing, which may occur while inpatient, or outpatient if rapid escalation of care is available. Appropriate or protocolized outpatient management may potentially lead to unnecessary admissions, considering only 0.6-4% of patients develop grade 3 or 4 CRS. However, the potential benefits and safety implications of this practice are only theorized.

Objective: This study aims to assess the current practice of outpatient management of bispecific related toxicities, including patient outcomes, admission rates, and resource utilization.

Methods: This is an observational cohort study of adult patients who have received bispecific therapy for multiple myeloma or lymphoma and received initial treatment for CRS in the outpatient setting. Data collection will be performed by retrospective chart review. Due to the novelty of this practice, patients will be actively enrolled into this study as they receive bispecific therapy.

Results: Pending.

Discussion/

Conclusion: We hypothesize that management of grade 1 CRS in the outpatient setting is associated with lower rates of admission and resource utilization.

References (must also be included in final poster): 1. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495-505. doi:10.1056/NEJMoa22034782.

2. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387(24):2232-2244. doi:10.1056/NEJMoa22045913.

3. Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results [published online ahead of print, 2023 Aug 15]. Nat Med. 2023;10.1038/s41591-023-02528-9. doi:10.1038/s41591-023-02528-9

4. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;387(24):2220-2231. doi:10.1056/NEJMoa2206913

5. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023

6. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022

7. Tecvayli [package insert]. Horsham, PA; Janssen Biotech, Inc.; October 2022. Accessed October, 2023.

8. Talvey [package insert]. Horsham, PA; Janssen Biotech, Inc.; August 2023. Accessed October, 2023.

9. Elrexfio [package insert]. New York, NY; Pfizer Inc.; August 2023. Accessed October, 2023.

10. Lunsumio [package insert]. South San Francisco, CA; Genetech, Inc.; December 2022. Accessed October 2023.

11. Columvi [package insert]. South San Francisco, CA; Genetech, Inc.; June 2023. Accessed October, 2023.

12. Epkinly [package insert]. North Chicago, IL; Genmab US, Inc.; May 2023. Accessed October, 2023.

13. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758

14. Rajkumar SV. Management of Teclistamab Cytokine Release Syndrome (CRS) and Immune Cell Associated Neurotoxicity Syndrome (ICANS). Mayo Stratification for Myeloma and Risk Adapted Therapy. Updated January 2023. Accessed October 8th, 2023.

15. Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology. 2022 Jun 1;11(1):2083479. doi: 10.1080/2162402X.2022.2083479. PMID: 35694193; PMCID: PMC9176235.

16. Lancman G, Sastow DL, Cho HJ, Jagannath S, Madduri D, Parekh SS, Richard S, Richter J, Sanchez L, Chari A. Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discov. 2021 Aug 17;2(5):423-433. doi: 10.1158/2643-3230.BCD-21-0028. PMID: 34661161; PMCID: PMC8510808.

17. Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, Huang Y, Xu Y, Qian C. Bispecific Antibodies: From Research to Clinical Application. Front Immunol. 2021 May 5;12:626616. doi: 10.3389/fimmu.2021.626616. PMID: 34025638; PMCID: PMC8131538.